A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. (Q39580436)
Jump to navigation
Jump to search
scientific article published on 25 July 2012
Language | Label | Description | Also known as |
---|---|---|---|
English | A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. |
scientific article published on 25 July 2012 |
Statements
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer (English)
Gary Hudes
Scott T Tagawa
Ming Qi
Xiang Qin
Thomas A Puchalski
Manjula Reddy
Mark Cornfeld
Mario Eisenberger
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference